Varun Sundaram
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Varun Sundaram has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Padmini Selvaganesan
Case Western Reserve University School of Medicine
6 shared publications Jayakumar Sahadevan
Case Western Reserve University, Cleveland, Ohio, USA
5 shared publicationsMohamad Karnib
Case Western Reserve University School of Medicine
5 shared publications- Irfan Helmy
Case Western Reserve University School of Medicine
4 shared publications - Rosita Zakeri
School of Cardiovascular Medicine & Sciences, James Black Centre, King’s College London, United Kingdom (R.Z.).
4 shared publications - Salil Vasudeo Deo
Case School of Medicine, Case Western Reserve University, Cleveland, USA
4 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (21)
Glucagon‐Like Peptide‐1 Receptor Agonists in Obese Heart Failure With Preserved Ejection Fraction
Background: To evaluate whether GLP‐1 (glucagon‐like peptide‐1) receptor agonists (GLP‐1RAs), compared with DPP4 (dipeptidyl peptidase‐4) inhibitors or sulfonylureas, are associated with reduced all‐cause mortality or heart failure hospitalizations in patients with obesity and type 2 diabetes, and heart failure with preserved ejection fraction. Methods: PRAISE‐HFpEF (Glucagon‐Like Peptide‐1 Receptor Agonist in Obese Heart Failure With Preserved Ejection Fraction) was a nationwide multicenter cohort study using a new‐user, active‐comparator design within the national Veterans Affairs Health System (170 US hospitals). Adults with type 2 diabetes between January 1, 2000 and December 31, 2021, were identified from centralized electronic health records. Patients with heart failure with preserved ejection fraction and a body mass index ≥30 kg/m 2 were selected using a validated diagnostic algorithm. Exposure was initiation of a GLP‐1RA versus DPP4 inhibitors/sulfonylurea from January 1, 2015 to December 31, 2021. The primary outcome was time to all‐cause mortality or heart failure hospitalization. Inverse probability of treatment weighting based on the propensity score was used to balanced baseline characteristics. Results: Among 179 288 patients with type 2 diabetes, obesity, and heart failure with preserved ejection fraction, 1024 GLP‐1RA users and 796 DPP4 inhibitors/sulfonylurea users met inclusion criteria. Over a median follow‐up of 1.5 years, GLP‐1RA use was associated with a lower risk of the primary outcome (adjusted hazard ratio, 0.78 [95% CI, 0.64–0.95], P =0.01). Weight loss was modestly greater with GLP‐1RAs compared with DPP4 inhibitors/sulfonylurea (−12.9% versus −10.1%). Conclusions: Among patients with obese heart failure with preserved ejection fraction and type 2 diabetes, GLP‐1RA initiation was associated with a lower incidence of death or heart failure hospitalization compared with alternative oral agents.
- 3 November 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (21)
Open AccessGlucagon‐Like Peptide‐1 Receptor Agonists in Obese Heart Failure With Preserved Ejection Fraction
Background: To evaluate whether GLP‐1 (glucagon‐like peptide‐1) receptor agonists (GLP‐1RAs), compared with DPP4 (dipeptidyl peptidase‐4) inhibitors or sulfonylureas, are associated with reduced all‐cause mortality or heart failure hospitalizations in patients with obesity and type 2 diabetes, and heart failure with preserved ejection fraction. Methods: PRAISE‐HFpEF (Glucagon‐Like Peptide‐1 Receptor Agonist in Obese Heart Failure With Preserved Ejection Fraction) was a nationwide multicenter cohort study using a new‐user, active‐comparator design within the national Veterans Affairs Health System (170 US hospitals). Adults with type 2 diabetes between January 1, 2000 and December 31, 2021, were identified from centralized electronic health records. Patients with heart failure with preserved ejection fraction and a body mass index ≥30 kg/m 2 were selected using a validated diagnostic algorithm. Exposure was initiation of a GLP‐1RA versus DPP4 inhibitors/sulfonylurea from January 1, 2015 to December 31, 2021. The primary outcome was time to all‐cause mortality or heart failure hospitalization. Inverse probability of treatment weighting based on the propensity score was used to balanced baseline characteristics. Results: Among 179 288 patients with type 2 diabetes, obesity, and heart failure with preserved ejection fraction, 1024 GLP‐1RA users and 796 DPP4 inhibitors/sulfonylurea users met inclusion criteria. Over a median follow‐up of 1.5 years, GLP‐1RA use was associated with a lower risk of the primary outcome (adjusted hazard ratio, 0.78 [95% CI, 0.64–0.95], P =0.01). Weight loss was modestly greater with GLP‐1RAs compared with DPP4 inhibitors/sulfonylurea (−12.9% versus −10.1%). Conclusions: Among patients with obese heart failure with preserved ejection fraction and type 2 diabetes, GLP‐1RA initiation was associated with a lower incidence of death or heart failure hospitalization compared with alternative oral agents.
- 2 November 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
Antecedent Kidney Function and Cardiovascular Mortality in Over 300 000 Patients With Incident Heart Failure With Preserved Ejection Fraction
BACKGROUND: Chronic kidney disease is a frequent comorbidity in heart failure with preserved ejection fraction (HFpEF) and has been proposed as a contributor to its development. However, the spectrum of antecedent kidney function before incident HFpEF and its association with subsequent cardiovascular outcomes remains unclear. METHODS: We conducted a multicenter cohort study across 170 US Veterans Affairs hospitals, including patients with incident HFpEF diagnosed between January 1, 2000, and June 30, 2025. HFpEF was ascertained using natural language processing-derived left ventricular ejection fraction ≥50% closest to the incident HF date and a validated HFpEF algorithm incorporating loop diuretic use, elevated natriuretic peptide levels, and an HFpEF–age, body mass index, and atrial fibrillation score >0.5. Antecedent kidney function was classified using 2 estimated glomerular filtration rate (eGFR) measurements obtained ≥90 days apart before incident HFpEF and urine albumin-to-creatinine ratio. We characterized antecedent kidney function, including albuminuria (urine albumin-to-creatinine ratio ≥30 mg/g), and examined its associations with 5-year cardiovascular death and heart failure hospitalization. Competing-risk analysis was performed accounting for noncardiovascular death as a competing event for cardiovascular death. RESULTS: Of 304 712 patients meeting HFpEF ascertainment criteria, 236 910 comprised the final cohort; 51% had antecedent eGFR ≥60 mL/min per 1.73m 2 . Overall, 15% had an eGFR ≥90 mL/min per 1.73m 2 . Patients with eGFR 2 were older and had more diabetes and hypertension. 51% of the patients with eGFR 2 had body mass index 2 , including 20% with body mass index 2 . Progressively lower antecedent kidney function was associated with graded increases in cardiovascular death and heart failure hospitalization. Among decedents, the proportion of deaths attributed to cardiovascular causes increased from 25% in the preserved eGFR (≥90 mL/min per 1.73m 2 ) without documented albuminuria to 32% with albuminuria and 38% with advanced kidney dysfunction ( P <0.001). CONCLUSIONS: In this nationwide study of patients with incident HFpEF, antecedent kidney dysfunction was common but not uniformly present before HFpEF onset. Furthermore, among patients who developed HFpEF, antecedent kidney dysfunction identified a higher-risk phenotype, with progressively greater cardiovascular mortality and heart failure hospitalization with declining kidney function.
- 2 November 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
Antecedent Kidney Function and Cardiovascular Mortality in Over 300 000 Patients With Incident Heart Failure With Preserved Ejection Fraction
BACKGROUND: Chronic kidney disease is a frequent comorbidity in heart failure with preserved ejection fraction (HFpEF) and has been proposed as a contributor to its development. However, the spectrum of antecedent kidney function before incident HFpEF and its association with subsequent cardiovascular outcomes remains unclear. METHODS: We conducted a multicenter cohort study across 170 US Veterans Affairs hospitals, including patients with incident HFpEF diagnosed between January 1, 2000, and June 30, 2025. HFpEF was ascertained using natural language processing-derived left ventricular ejection fraction ≥50% closest to the incident HF date and a validated HFpEF algorithm incorporating loop diuretic use, elevated natriuretic peptide levels, and an HFpEF–age, body mass index, and atrial fibrillation score >0.5. Antecedent kidney function was classified using 2 estimated glomerular filtration rate (eGFR) measurements obtained ≥90 days apart before incident HFpEF and urine albumin-to-creatinine ratio. We characterized antecedent kidney function, including albuminuria (urine albumin-to-creatinine ratio ≥30 mg/g), and examined its associations with 5-year cardiovascular death and heart failure hospitalization. Competing-risk analysis was performed accounting for noncardiovascular death as a competing event for cardiovascular death. RESULTS: Of 304 712 patients meeting HFpEF ascertainment criteria, 236 910 comprised the final cohort; 51% had antecedent eGFR ≥60 mL/min per 1.73m 2 . Overall, 15% had an eGFR ≥90 mL/min per 1.73m 2 . Patients with eGFR 2 were older and had more diabetes and hypertension. 51% of the patients with eGFR 2 had body mass index 2 , including 20% with body mass index 2 . Progressively lower antecedent kidney function was associated with graded increases in cardiovascular death and heart failure hospitalization. Among decedents, the proportion of deaths attributed to cardiovascular causes increased from 25% in the preserved eGFR (≥90 mL/min per 1.73m 2 ) without documented albuminuria to 32% with albuminuria and 38% with advanced kidney dysfunction ( P <0.001). CONCLUSIONS: In this nationwide study of patients with incident HFpEF, antecedent kidney dysfunction was common but not uniformly present before HFpEF onset. Furthermore, among patients who developed HFpEF, antecedent kidney dysfunction identified a higher-risk phenotype, with progressively greater cardiovascular mortality and heart failure hospitalization with declining kidney function.
- 1 October 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (10)
Cardiac Resynchronization With or Without Defibrillator in Nonischemic Cardiomyopathy: A Nationwide Cohort Study (DECIDE-CRT)
BACKGROUND: With evolving therapy for heart failure with reduced ejection fraction, the benefits of adding a defibrillator in patients undergoing cardiac resynchronization therapy (CRT) remain unclear, particularly for nonischemic cardiomyopathy (NICM). This study evaluates long-term survival among patients with NICM treated with CRT defibrillator (CRT-D) versus CRT pacemaker (CRT-P). METHODS: DECIDE-CRT (Cardiac Resynchronization With or Without Defibrillator in Non-Ischemic Cardiomyopathy) is a multicenter cohort study across 170 US Veterans Affairs hospitals. We identified patients with NICM receiving primary-prevention CRT-P or CRT-D between January 1, 2006, and December 31, 2020. Using a propensity score approach, we applied inverse probability of treatment weighting to balance baseline characteristics between the CRT-P and CRT-D groups. An inverse probability of treatment weighting–weighted Cox model estimated hazards for all-cause mortality. Secondary outcomes included generator replacement, device-related infections, hospitalization for heart failure, and ventricular arrhythmias. RESULTS: Of 16 609 CRT recipients, 3965 met NICM primary-prevention criteria (CRT-D=3158; CRT- P =807). At baseline, patients with NICM receiving CRT-P were much older, with more cardiovascular and noncardiovascular comorbidities compared with the CRT-D group. During the median follow-up of 5.2 years, the mortality rate for CRT-P versus CRT-D was 9.46 versus 9.21 per 100 person-years (rate ratio, 0.97 [95% CI, 0.71–1.13]; P =0.66). The adjusted hazard ratio for all-cause mortality using the inverse probability of treatment weighting-Cox model was 0.90 (95% CI, 0.71–1.13; P =0.34). There was no difference in adjusted hazard for heart failure hospitalization (hazard ratio, 1.27 [95% CI, 0.86–1.87]), while the CRT-D group had higher rates of generator replacement and device-related infections. CONCLUSIONS: This nationwide observational study from the Veterans Affairs Health system did not demonstrate a clear survival advantage with the addition of a defibrillator among patients with NICM receiving CRT although residual confounding cannot be excluded. Given the uncertainty surrounding the incremental benefit of the defibrillator in this setting, a randomized trial is needed to test the incremental value of CRT-D over CRT-P in NICM.
- 1 October 2026
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 19 (10)
Cardiac Resynchronization With or Without Defibrillator in Nonischemic Cardiomyopathy: A Nationwide Cohort Study (DECIDE-CRT)
BACKGROUND: With evolving therapy for heart failure with reduced ejection fraction, the benefits of adding a defibrillator in patients undergoing cardiac resynchronization therapy (CRT) remain unclear, particularly for nonischemic cardiomyopathy (NICM). This study evaluates long-term survival among patients with NICM treated with CRT defibrillator (CRT-D) versus CRT pacemaker (CRT-P). METHODS: DECIDE-CRT (Cardiac Resynchronization With or Without Defibrillator in Non-Ischemic Cardiomyopathy) is a multicenter cohort study across 170 US Veterans Affairs hospitals. We identified patients with NICM receiving primary-prevention CRT-P or CRT-D between January 1, 2006, and December 31, 2020. Using a propensity score approach, we applied inverse probability of treatment weighting to balance baseline characteristics between the CRT-P and CRT-D groups. An inverse probability of treatment weighting–weighted Cox model estimated hazards for all-cause mortality. Secondary outcomes included generator replacement, device-related infections, hospitalization for heart failure, and ventricular arrhythmias. RESULTS: Of 16 609 CRT recipients, 3965 met NICM primary-prevention criteria (CRT-D=3158; CRT- P =807). At baseline, patients with NICM receiving CRT-P were much older, with more cardiovascular and noncardiovascular comorbidities compared with the CRT-D group. During the median follow-up of 5.2 years, the mortality rate for CRT-P versus CRT-D was 9.46 versus 9.21 per 100 person-years (rate ratio, 0.97 [95% CI, 0.71–1.13]; P =0.66). The adjusted hazard ratio for all-cause mortality using the inverse probability of treatment weighting-Cox model was 0.90 (95% CI, 0.71–1.13; P =0.34). There was no difference in adjusted hazard for heart failure hospitalization (hazard ratio, 1.27 [95% CI, 0.86–1.87]), while the CRT-D group had higher rates of generator replacement and device-related infections. CONCLUSIONS: This nationwide observational study from the Veterans Affairs Health system did not demonstrate a clear survival advantage with the addition of a defibrillator among patients with NICM receiving CRT although residual confounding cannot be excluded. Given the uncertainty surrounding the incremental benefit of the defibrillator in this setting, a randomized trial is needed to test the incremental value of CRT-D over CRT-P in NICM.
- Open Access
- 20 August 2026
- Published by BMJ in BMJ Medicine
- Vol. 5 (1) , e002380
Clinical effectiveness of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: nationwide cohort study (REFINE-HFpEF)
Objective: To evaluate the clinical effectiveness of sodium glucose cotransporter 2 (SGLT2) inhibitors in reducing the risk of hospital admission for heart failure and mortality in a contemporary nationwide cohort of patients with heart failure with preserved ejection fraction (HFpEF). Design: Nationwide cohort study (REFINE-HFpEF). Setting: 170 veteran health medical centres across the US, 1 January 2014 to 31 December 2021. Participants: 2177 patients with type 2 diabetes and HFpEF; 1129 patients were newly prescribed SGLT2 inhibitors and 1048 were newly prescribed dipeptidyl peptidase 4 (DPP4) inhibitors or sulfonylureas. Main outcome measures: The primary outcome was a composite of all cause mortality and hospital admission for heart failure. Secondary outcomes included all cause mortality only and serial changes in body weight. Hazard ratios were derived from Cox proportional hazards models, incorporating inverse probability of treatment weighting based on propensity scores to account for confounding. Results: From a validated cohort of 179 288 patients with type 2 diabetes and HFpEF, the study included 1129 new users of SGLT2 inhibitors (active treatment) and 1048 new users of DPP4 inhibitors or sulfonylureas (comparators). After a median follow-up of 2.63 years, 46.4% of the study population had at least one hospital admission for heart failure (n=1011) and the overall mortality rate was 45.9% (n=1000). Use of SGLT2 inhibitors was associated with a relative risk reduction in the primary composite outcome of 18% compared with the use of DPP4 inhibitors or sulfonylureas (hazard ratio 0.82, 95% confidence interval 0.70 to 0.96; P=0.01). The adjusted hazard ratio for all cause mortality only was 0.73 (0.60 to 0.89; P=0.002). Weight loss was similar in the two groups. Conclusions: In this large, contemporary, nationwide cohort of patients with HFpEF, type 2 diabetes, and high event rates, starting SGLT2 inhibitors was associated with a significantly lower risk of hospital admission for heart failure and all cause mortality compared with starting treatment with DPP4 inhibitors or sulfonylureas.
- 20 August 2026
- Published by BMJ in BMJ Medicine
- Vol. 5 (1) , e002380
Open AccessClinical effectiveness of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: nationwide cohort study (REFINE-HFpEF)
Objective: To evaluate the clinical effectiveness of sodium glucose cotransporter 2 (SGLT2) inhibitors in reducing the risk of hospital admission for heart failure and mortality in a contemporary nationwide cohort of patients with heart failure with preserved ejection fraction (HFpEF). Design: Nationwide cohort study (REFINE-HFpEF). Setting: 170 veteran health medical centres across the US, 1 January 2014 to 31 December 2021. Participants: 2177 patients with type 2 diabetes and HFpEF; 1129 patients were newly prescribed SGLT2 inhibitors and 1048 were newly prescribed dipeptidyl peptidase 4 (DPP4) inhibitors or sulfonylureas. Main outcome measures: The primary outcome was a composite of all cause mortality and hospital admission for heart failure. Secondary outcomes included all cause mortality only and serial changes in body weight. Hazard ratios were derived from Cox proportional hazards models, incorporating inverse probability of treatment weighting based on propensity scores to account for confounding. Results: From a validated cohort of 179 288 patients with type 2 diabetes and HFpEF, the study included 1129 new users of SGLT2 inhibitors (active treatment) and 1048 new users of DPP4 inhibitors or sulfonylureas (comparators). After a median follow-up of 2.63 years, 46.4% of the study population had at least one hospital admission for heart failure (n=1011) and the overall mortality rate was 45.9% (n=1000). Use of SGLT2 inhibitors was associated with a relative risk reduction in the primary composite outcome of 18% compared with the use of DPP4 inhibitors or sulfonylureas (hazard ratio 0.82, 95% confidence interval 0.70 to 0.96; P=0.01). The adjusted hazard ratio for all cause mortality only was 0.73 (0.60 to 0.89; P=0.002). Weight loss was similar in the two groups. Conclusions: In this large, contemporary, nationwide cohort of patients with HFpEF, type 2 diabetes, and high event rates, starting SGLT2 inhibitors was associated with a significantly lower risk of hospital admission for heart failure and all cause mortality compared with starting treatment with DPP4 inhibitors or sulfonylureas.
- Open Access
- 17 April 2026
- Published by Elsevier in Clinical Medicine
- Vol. 26 (3) , 100584
Hypertension and heart failure: Navigating blood pressure targets and medication titration and tolerance
- 17 April 2026
- Published by Elsevier in Clinical Medicine
- Vol. 26 (3) , 100584
Open AccessHypertension and heart failure: Navigating blood pressure targets and medication titration and tolerance
- Open Access
- 27 February 2024
- Published by Elsevier in JACC: Advances
- Vol. 3 (4) , 100872
Statin Therapy in Heart Failure With Preserved Ejection Fraction
- 27 February 2024
- Published by Elsevier in JACC: Advances
- Vol. 3 (4) , 100872
Open AccessStatin Therapy in Heart Failure With Preserved Ejection Fraction
- 1 September 2022
- Published by Springer Nature in Indian Journal of Thoracic and Cardiovascular Surgery
- Vol. 38 (5) , 562-565
The importance of randomization in clinical research
Studies evaluating average treatment effects (ATE) of an intervention could broadly be classified into those with observational and randomized designs. Observational studies are limited by confounding, in addition to selection and information bias, making the evaluation of ATE hypothesis generating and not hypothesis testing. Randomization attempts to reduce the systemic error introduced by observational studies by ensuring equal distribution of prognostic factors between the treatment and control groups, thereby confirming that any difference in outcomes observed between the two groups is attributable to the treatment. While randomized controlled trials (RCT) remain the gold standard in estimating ATE of therapeutic interventions, they do have inherent limitations due to uncertain external validity. Observational studies can have a complementary role in enhancing RCTs' ability to inform routine clinical practice. In this review, we focus on the limitations of observational studies, the need for randomization, interpretation, and the limitations of RCTs.
- 1 September 2022
- Published by Springer Nature in Indian Journal of Thoracic and Cardiovascular Surgery
- Vol. 38 (5) , 562-565
The importance of randomization in clinical research
Studies evaluating average treatment effects (ATE) of an intervention could broadly be classified into those with observational and randomized designs. Observational studies are limited by confounding, in addition to selection and information bias, making the evaluation of ATE hypothesis generating and not hypothesis testing. Randomization attempts to reduce the systemic error introduced by observational studies by ensuring equal distribution of prognostic factors between the treatment and control groups, thereby confirming that any difference in outcomes observed between the two groups is attributable to the treatment. While randomized controlled trials (RCT) remain the gold standard in estimating ATE of therapeutic interventions, they do have inherent limitations due to uncertain external validity. Observational studies can have a complementary role in enhancing RCTs' ability to inform routine clinical practice. In this review, we focus on the limitations of observational studies, the need for randomization, interpretation, and the limitations of RCTs.
- 1 March 2022
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 28 (3) , 353-366
Hospitalization for Heart Failure in the United States, UK, Taiwan, and Japan: An International Comparison of Administrative Health Records on 413,385 Individual Patients
- 1 March 2022
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 28 (3) , 353-366
Hospitalization for Heart Failure in the United States, UK, Taiwan, and Japan: An International Comparison of Administrative Health Records on 413,385 Individual Patients
- 21 February 2022
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 8 (2) , 222-224
Cardiac Resynchronization Therapy
- 21 February 2022
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 8 (2) , 222-224
Cardiac Resynchronization Therapy